WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Grasse BIOTECH
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Medical
Invenshure | June 03, 2022
Venture studio Invenshure announces the launch of MEKanistic Therapeutics, a biotechnology company redefining precision oncology. Co-inventors and pioneers in the MEK inhibitor field, Judith Sebolt-Leopold, PhD, and Christopher Whitehead, PhD, MBA, have rationally designed a drug that blocks two, key pathways (EGFR and PI3K) used to signal cancer cell growth, with a single molecule. In preclinical studies, this first-in-class dual inhibitor shows unparalleled tumor shrinkage without the toxicity...
MedTech
NeuroSense and NeuraLight | July 29, 2022
NeuroSense Therapeutics Ltd. a company developing treatments for severe neurodegenerative diseases, and NeuraLight, a company developing objective and sensitive biomarkers for neurological disorders, today announced a collaboration to advance the science of digital biomarkers in the detection and monitoring of neurological diseases including amyotrophic lateral sclerosis. NeuraLight's platform, uses proprietary computer vision and deep learning algorithms to extract over 100 o...
Industrial Impact
Envisagenics | December 05, 2022
Envisagenics, an Artificial Intelligence driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol Myers Squibb. The multi-year collaboration will leverage Envisagenics' SpliceCore® AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb's vast oncology pipeline. Envisagenics will receive an upfront payment and milestone payments based ...
AI, Industrial Impact
Cimeio | December 12, 2022
The two studies demonstrate proof-of-concept that genetically engineered variants of cell surface receptors harboring single amino acid substitutions are fully functional but evade a paired immunotherapy directed against the wild-type molecule. This technology will enable the development of more efficient and safer targeted conditioning regimens for hematopoietic stem cell transplantation, gene therapies, and opens the path to more efficient cell and immunotherapy-based treatment approaches for ...
Research, Medical
Whitepaper
Industrial Impact, Medical
Cell and Gene Therapy
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE